|
|
Article: AMDL Diagnostics, Inc. Enters Into Exclusive Distribution Agreement With Grifols USA, LLC to Advance Commercialization of DR-70 Onko-Sure™ Cancer Test.
- Article from:
- Cancer Weekly
- Article date:
- October 20, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Radient Pharmaceuticals Corporation (NYSE Amex: RPC), a US-based pharmaceutical company through its wholly-owned subsidiary AMDL Diagnostics, Inc. (ADI) announced it has entered into an exclusive 5-year marketing and distribution agreement with Grifols USA, LLC. Under the terms of the agreement, Grifols USA, LLC will market and sell ADI's DR-70 Onko-Sure cancer test for the monitoring of colorectal cancer (CRC) to hospitals, clinical labs, clinics, and other healthcare organizations throughout the US (see also Colon Cancer).
Grifols is a publicly-traded, multinational healthcare products manufacturer and distributor. The company has business operations in more ...
Related newspaper, magazine, and journal articles:
|
|
Article: Radient Pharma Enters Into Distribution Agreement to Launch Sales ...
PR Newswire;
October 6, 2009 ;
700+ words
... ... Ltd. for the marketing and sales of its Onko-Sure(TM) in vitro diagnostic (IVD ... Pharmaceuticals' commercialization strategy for Onko-Sure(TM) (previously marketed as ... agreement, Tarom will market and distribute Onko-Sure(TM) to medical centers, hospitals ...
|
|